Histone deacetylase 2 cell autonomously suppresses excitatory and enhances inhibitory synaptic function in CA1 pyramidal neurons

Journal of Neuroscience

Volumn 33, Issue 14, 2013, Pages 5924-5929

  Hanson, Jesse E ^a   Deng, Lunbin ^a   Hackos, David H ^a   Lo, Shih Ching ^a   Lauffer, Benjamin E ^a   Steiner, Pascal ^a   Zhou, Qiang ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; HISTONE DEACETYLASE 2;

ANIMAL TISSUE; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; EVOKED RESPONSE; EXCITATION; EXCITATORY POSTSYNAPTIC POTENTIAL; GENE EXPRESSION; HIPPOCAMPAL CA1 REGION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INHIBITORY POSTSYNAPTIC POTENTIAL; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; POSTSYNAPTIC MEMBRANE; PRIORITY JOURNAL; PYRAMIDAL NERVE CELL; RAT; SYNAPTIC INHIBITION; SYNAPTIC TRANSMISSION; WESTERN BLOTTING;

EID: 84876001504     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.3162-12.2013     Document Type: Article

References (18)

1. Akhtar MW, Raingo J, Nelson ED, Montgomery RL, Olson EN, Kavalali ET, MonteggiaLM (2009) Histone deacetylases 1 and 2 form a developmental switch that controls excitatory synapse maturation and function. J Neurosci 29:8288-8297. CrossRef Medline
2. Buchwald M, Krämer OH, Heinzel T (2009) HDACi: targets beyond chromatin. Cancer Lett 280:160-167. CrossRef Medline
3. Deng L, Kaeser PS, Xu W, Südhof TC (2011) RIM proteins activate vesicle priming by reversing autoinhibitory homodimerization of Munc13. Neuron 69:317-331. CrossRef Medline
4. Essrich C, Lorez M, Benson JA, Fritschy JM, Lüscher B (1998) Postsynaptic clustering of major GABAA receptor subtypes requires the gamma 2 subunit and gephyrin. Nat Neurosci 1:563-571. CrossRef Medline
5. Fang C, Deng L, Keller CA, Fukata M, Fukata Y, Chen G, Lüscher B (2006) GODZ-mediated palmitoylation of GABAA receptors is required for normal assembly and function of GABAergic inhibitory synapses. J Neurosci 26:12758-12768. CrossRef Medline
6. Fischer A, Sananbenesi F, Mungenast A, Tsai LH (2010) Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 31:605-617. CrossRef Medline
7. Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A (2011) Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis 26:187-197. CrossRef Medline
8. Gräff J, Rei D, Guan JS, Wang WY, Seo J, Hennig KM, Nieland TJ, Fass DM, Kao PF, Kahn M, Su SC, Samiei A, Joseph N, Haggarty SJ, Delalle I, Tsai LH (2012) An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483:222-226. CrossRef Medline
9. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, Nieland TJ, Zhou Y, Wang X, Mazitschek R, Bradner JE, DePinho RA, Jaenisch R, Tsai LH (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459:55-60. CrossRef Medline
10. Gutiérrez R, Heinemann U (1999) Synaptic reorganization in explanted cultures of rat hippocampus. Brain Res 815:304-316. CrossRef Medline
11. Jacob TC, Moss SJ, Jurd R (2008) GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition. Nat Rev Neurosci 9:331-343. CrossRef Medline
12. Jenuwein T, Allis CD (2001) Translating the histone code. Science 293: 1074-1080. CrossRef Medline
13. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, Sweatt JD, Rumbaugh G (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35:870-880. CrossRef Medline
14. Li RW, Yu W, Christie S, Miralles CP, Bai J, Loturco JJ, De Blas AL (2005) Disruption of postsynaptic GABA receptor clusters leads to decreased GABAergic innervation of pyramidal neurons. J Neurochem 95:756-770. CrossRef Medline
15. Ocker M (2010) Deacetylase inhibitors: focus on non-histone targets and effects. World J Biol Chem 1:55-61. CrossRef Medline
16. Ricobaraza A, Cuadrado-Tejedor M, Pérez-Mediavilla A, Frechilla D, Del Río J, García-Osta A (2009) Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 34:1721-1732. CrossRef Medline
17. Ricobaraza A, Cuadrado-Tejedor M, Marco S, Pérez-Otaño I, García-Osta A (2012) Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 22: 1040-1050. CrossRef Medline
18. Strahl BD, Allis CD (2000) The language of covalent histone modifications. Nature 403:41-45. CrossRef Medline